Close Menu

NEW YORK (GenomeWeb) – Japan's Pharmaceuticals and Medical Devices Agency has approved olaparib (Lynparza) as a first-line maintenance treatment after BRCA-mutated advanced ovarian cancer patients have responded to platinum-based chemotherapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.